Preclinical studies have demonstrated that KL-50 induces DNA interstrand crosslinks selectively in MGMT-silenced tumor models and retains activity in the absence of functional MMR, highlighting its potential to fill a critical therapeutic gap in recurrent, treatment-refractory tumors. Here, MRC1 is linked to neoplasm.